Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation
Open Access
- 6 June 2013
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 8 (2), 439-445
- https://doi.org/10.3892/mmr.2013.1512
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease worldwide. Recent studies have reported that oxymatrine (OMT), an active monomer isolated from Sophora flavescens Ait. (kushen), ameliorates NAFLD in rats. In order to explore the possible molecular mechanism involved, we used an NAFLD rat model with hyperlipidemia, which had been established by feeding a high‑fructose diet (HFD) for eight weeks, and the model rats were subsequently treated with OMT (80 mg/kg/day) for a further four weeks. We evaluated the expression of genes and proteins regulating fatty acid oxidation and lipid export in the liver using quantitative (q)PCR and western blot analysis. The NAFLD model rats developed dyslipidaemia, hepatic steatosis and insulin resistance (IR). OMT administration for four weeks reduced body weight gain and visceral fat weight, decreased serum triglyceride (TG), total cholesterol (TC), free fatty acid (FFA) and fasting serum insulin (FinS) levels and lowered liver TG contents. It also increased the glucose infusion rate (GIR), indicative of a reduction in IR. Moreover, OMT treatment markedly increased the mRNA and protein levels of peroxisome proliferator-activated receptor-α (PPARα), carnitine palmitoyltransferase 1A (CPT1A) and microsomal triglyceride transfer protein (MTTP). The beneficial effects of OMT were further confirmed by the observation of a decrease in lipid accumulation in the histology of the liver. Our results indicate that OMT may be used to treat NAFLD.Keywords
This publication has 22 references indexed in Scilit:
- Differing Endoplasmic Reticulum Stress Response to Excess Lipogenesis versus Lipid Oversupply in Relation to Hepatic Steatosis and Insulin ResistancePLOS ONE, 2012
- Lipocalin 13 Protein Protects against Hepatic Steatosis by Both Inhibiting Lipogenesis and Stimulating Fatty Acid β-OxidationOnline Journal of Public Health Informatics, 2011
- Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Antiarrhythmic effects and ionic mechanisms of oxymatrine from Sophora flavescensPhytotherapy Research, 2010
- Matrine inhibits 3T3-L1 preadipocyte differentiation associated with suppression of ERK1/2 phosphorylationBiochemical and Biophysical Research Communications, 2010
- ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob miceJournal of Lipid Research, 2008
- A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levelsAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered miceJCI Insight, 2008
- Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2008
- Nonalcoholic Steatohepatitis (NASH) in OB/OB Mice Treated with Yo Jyo Hen Shi Ko (YHK): Effects on Peroxisome Proliferator-Activated Receptors (PPARs) and Microsomal Triglyceride Transfer Protein (MTP)Digestive Diseases and Sciences, 2007